蒙梓棋
助理教授(藥理學)
辦公室 擎天匯校區 PP-R209b
電子信箱 omonteiro@must.edu.mo
Dr. Olivia Monteiro completed her undergraduate degree in Biomedical Sciences at the University of Aberdeen, UK before earning her PhD from the University of Edinburgh, UK in 2010. With a primary focus on neuropharmacology and cognitive neuroscience, her laboratory investigates the impacts of early life adversities and neurodegenerative diseases on cognitive function. Her research focuses on the pharmacological manipulations of GABAARs to impair or to enhance cognition. Additionally, her laboratory explores the emerging phenomenon of long COVID, examining alterations in immune mediators and neurotransmitter levels within the local population. Through her interdisciplinary approach, Dr. Olivia Monteiro aims to contribute to the advancement of both basic and clinical neuroscience, with the ultimate goal of improving cognitive health in individuals affected by cognitive impairments.
學歷

2010: PhD, University of Edinburgh; Mechanisms of Dendritic Peptide Release. BBSRC studentship 2004: BSc. Hons, University of Aberdeen; Biomedical Sciences (Pharmacology)

教學領域

Pharmacology, Physiology, Neuroscience, Language and Communication

研究領域

Neuropharmacology, cognitive neuroscience, behavioural neuroscience, early life adversity, post-operative cognitive deficits caused by general anaesthesia, long COVID

工作經歷

2020 – present: Assistant professor 2012 – 2019: Postdoctoral Research Scientist, School of Medicine, University of Dundee 2009 – 2011: Postdoctoral Research Scientist, School of Life Science, University of Dundee.

學術出版物(精選)

1. Wong IN*, Monteiro O*, Baptista-Hon D, Wang K, Lu Wy, Sun Z, Nei S, Yin Y (2024, in press). Leveraging foundation and large language models in medical artificial intelligence Chinese Medical Journal. IF 7.5. 1st Author

 

2. Zhang S, Yang B, Yang H, Zhao J, Zhang Y, Gao Y, Monteiro O, Zhang K, Liu B, Wang S (June 2024). Potential rapid intraoperative cancer diagnosis using dynamic full-field optical coherence tomography and deep learning: A prospective cohort study in breast cancer patients. Science Bulletin. IF 18.9. Contributing Author

 

3. Sarkar S and Monteiro O (April 2024) Understanding long COVID—The role of serotonin in cognitive impairment MedComm – Future Medicine Corresponding Author

 

4. Guan T, Monteiro O, Chen D, Luo Z, Chi K, Li Z, Liang Y, Lu Z, Jiang Y, Yang J, Lin W, Yi M, Zhang K, Ou C (26/03/2024). Long-term and short-term cardiovascular disease mortality among patients of 21 non[1]metastatic cancers. Journal of Advanced Research. IF 10.7. 2nd Author

 

5. Ye Y, Tong HYK, Chong WH, Li Z, Tam PKH, Baptista-Hon DT, Monteiro O (18/02/2024). A systematic review and meta-analysis of the effects of long-term antibiotic use on cognitive outcomes. Scientific Reports. IF 5.5. Corresponding Author

 

6. Zhou X, He Y, Xu T, Wu Z, Guo W, Xu X, Liu Y, Zhang Y, Shang H, Huang L, Yao Z, Li Z, Su L, Li Z, Feng T, Zhang S, Monteiro O, Cunha RA, Huang ZL, Zhang K, Li Y, Cai X, Qu J, Chen JF (08/02/2024). 40 Hz light flickering promotes sleep through cortical adenosine signaling. Cell Research. IF 44.1. Contributing Author

 

7. Wang J, Gao Y, Wang F, Zeng S, Li J, Miao H, Wang T, Zeng J, Baptista-Hon D, Monteiro O, Guan T, Cheng L, Lu Y, Luo Z, Li M, Zhu JK, Nie S, Zhang K, Zhou Y (08/01/2024). Accurate estimation of biological age and its application in disease prediction using a multimodal image Transformer system. PNAS. IF 11.1. Contributing Author

 

8. Li Z, He J, Yin Y, Tang L, Liu Y, Monteiro O, Zeng F (21/12/2023). SARS-CoV-2 pathogenesis in the gastrointestinal tract mediated by Spike-induced intestinal inflammation. Precision Clinical Medicine. IF 5.3. Corresponding Author

 

9. Ye Y, Sarkar S, Bhaskar A, Tomlinson B, Monteiro O (21/06/2023). Using ChatGPT in a clinical setting: A case report. MedComm – Future Medicine. Corresponding Author

 

10. Baptista-Hon DT, Fesalbon GJW, Monteiro O (21/11/2022). Changing clinical features of the 2022 monkeypox global health emergency. MedComm – Future Medicine. Contributing Author

 

11. Monteiro O (17/10/2022). How will previous infection or current vaccination strategies protect us from future SARS-CoV-2 variant infections? MedComm – Future Medicine. 1st Author

 

12. Monteiro O, Li YW, Baptista-Hon DT (16/08/2022). Phylogenomic characterization of the 2022 outbreak of monkeypox virus—The importance of sustained genetic surveillance. MedComm – Future Medicine. 1st Author

 

13. Zhou Z, Du P, Li N, Xiong X, Tang S, Dai Q, Wang T, Yu M, Man M, Lam K, Baptista-Hon DT, Tai WH, Monteiro O, Ng WS, Lee UM, Liu Z, Zhang K, Li G (June 2022). Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant. MedComm. IF 10.7. Contributing Author

 

14. Monteiro O, Bhaskar A, Wong IN, Ng AKM, Baptista-Hon DT (Dec 2021). Teaching bioelectricity and neurophysiology to medical students using LabAXON simulations. Adv Physiol Ed. IF 2.89. 1st Author

 

15. Monteiro O, Bhaskar A, Ng AKM, Murdoch CE, Baptista-Hon DT (Oct 2021). Computer-based virtual laboratory simulations: LabHEART cardiac physiology practical. Adv Physiol Ed. IF 2.89. 1st Author

 

16. Monteiro O, Chen CW, Bingham R, Rowland P, Argyrou A, Buxton R, Pancevec C, Jones E, Bridges A, Gatfield K, Krauss S, Lambert J, Langston R, Schweiger S, Uings I (2018). Pharmacological disruption of the MID-1/α4 interaction reduces mutant Huntingtin levels in primary neuronal cultures. Neuroscience Letters 673, pp. 44-50. IF 2.026. Contributing Author

 

17. King R, Monteiro O, Etherington L, Swinny J, Lambert JJ, Langston RF, Schweiger S (in preparation). Early cognitive and synaptic plasticity deficits in HdhQ111 mice are reversed by inhibition of α5- GABAA receptors. Neuropharmacology. IF 5.1026. Equal Contribution

 

18. Arnoux I, Willam M, Griesche N, Krummeich J, Watari H, Offermann N, Weber S, Dey NP, Chen CW, Monteiro O, Buettner S, Meyer K, Bano D, Radyushkin K, Langston RF, Lambert JJ, Wanker E, Methner A, Krauss S, Schweiger S, Stroh A (2018). Early cortical network dysfunction and behavior changes in a mouse model of Huntington’s Disease can be reversed by Metformin. eLife. IF 7.725. Contributing Author

 

19. Etherington L, Mihalik B, Pálvölgyi A, Ling I, Pallagi K, Gunn BG, Brown AR, Livesey MR, Monteiro O, Belelli D, Barkóczy J, Spedding M, Lambert JJ, Antoni FA (2017). Selective targeting of extra-synaptic α5-GABAA receptors by S44819 (Egis-13529), a novel competitive GABAA receptor inhibitor compound. Neuropharmacology 125, pp. 353-364. IF 5.1026. Contributing Author

 

20. Monteiro O, Wiegand UK, Ludwig M (2011). Vesicle degradation in dendrites of magnocellular neurones of the rat supraoptic nucleus. Neuroscience Letters 489, pp. 30-33. IF 2.026. 1st Author


書籍
專利
專業認證和獎項

RESEARCH FUNDING

 • FDCT General research grant (2022 – 2025) Selective inhibition of GABAARs on the treatment of postoperative cognitive deficit (POCD) caused by anaesthesia. (Grant value MOP 1,400,000) Principal investigator

• FDCT General research grant (2022 – 2024) Effects of Sinopharm BBIBP-CorV and BioNTech mRNA primary vaccination series and homologous and heterologous booster shots against SARS-CoV2 variants of concern in a local population in Macao. (Grant value MOP 644,000) Principal investigator 

• Macau University of Science and Technology Faculty Research Grant (2021-2022) - Relocalization of extrasynaptic α5-GABAA receptors causes memory loss and impairs long-term potentiation in a model of early life adversity (Grant value MOP 100,000). Principal investigator.

• FDCT General research grant (2021-2024) - The voltage-gated sodium channel NaV1.5 functions as an escape pathway from apoptosis in colon cancer cells (Grant value MOP 2,650,000). Co-investigator. 

• Society for Endocrinology Small Grant Programme for Scientific Research in Endocrinology (2007- 2008) – Mechanisms for dendritic peptide release (Grant value MOP 113,330) Co-investigator. 

• The G Lawrence fund (University of Dundee) 2015 and 2018. 

• Project and travel award for EMBO 3D developmental imaging course 2011

專業協會會員資格